Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267


Real-time Estimate Quote. Real-time Estimate Cboe Europe - 01/20 09:40:09 am
81.13 CHF   -0.41%
04:23aNOVARTIS AG : JP Morgan keeps a Sell rating
03:11a"SHOW MORE OF YOU" : Amgen V. Sandoz, Battling It Out On Amgen's Otezla« Drug
01/18Novartis CEO Expects Worldwide Normalcy to COVID-19 By 2022-End
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche shareholders approve deal to buy Novartis's $20.7 billion stake

11/26/2021 | 05:32am EST
FILE PHOTO: Swiss drugmaker Novartis' logo is seen in Stein

ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.

Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.

Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.

They also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.

Therefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.

"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche," said Roche Chairman Christoph Franz. "As a result, we will be even better positioned to make a contribution to the health of people around the world."

Novartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.

The repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.

Novartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.

Roche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.

(Reporting by John Revill, editing by Silke Koltrowitz)

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS AG -0.02% 81.41 Delayed Quote.1.47%
ROCHE HOLDING AG -0.16% 364.95 Delayed Quote.-3.53%
All news about NOVARTIS AG
04:23aNOVARTIS AG : JP Morgan keeps a Sell rating
03:11a"SHOW MORE OF YOU" : Amgen V. Sandoz, Battling It Out On Amgen's Otezla« Drug
01/18Novartis CEO Expects Worldwide Normalcy to COVID-19 By 2022-End
01/18GLOBAL MARKETS LIVE : Toyota, Microsoft, Goldman Sachs, Alibaba, Boeing...
01/18Molecular Partners Shares Drop 14% After Novartis Deal
01/18Wall Street Set for Downbeat Open Amid Rising Treasury Yields
01/18Health Care Stocks Retreat Pre-Bell Tuesday
01/18Top Premarket Decliners
01/18Medicenna Therapeutics up 12.7% in US Trade, Details Management Change, Appoints Develo..
01/18Molecular Partners to License Ensovibep to Novartis for COVID-19
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2021 52 061 M - -
Net income 2021 24 248 M - -
Net Debt 2021 7 912 M - -
P/E ratio 2021 8,22x
Yield 2021 3,68%
Capitalization 199 B 199 B -
EV / Sales 2021 3,97x
EV / Sales 2022 3,83x
Nbr of Employees 108 000
Free-Float 85,7%
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 88,95 $
Average target price 98,23 $
Spread / Average Target 10,4%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG1.47%199 080
JOHNSON & JOHNSON-2.62%438 538
ROCHE HOLDING AG-3.53%323 214
PFIZER, INC.-9.33%300 513
ABBVIE INC.-0.14%239 035
NOVO NORDISK A/S-12.67%223 059